Fig. 2.

Improvement in EQ-5D categories at 1 year among rituximab initiators, overall and by prior TNFi use. TNFi tumor necrosis factor inhibitor. a Percentage of patients reporting improvement among patients who reported difficulty in each measure at baseline. b Improvement in the EQ-5D domains was defined as either patients improving from moderate to no disability or those with severe disability improving to moderate or no disability